Takeda Pharmaceutical (TAK) to Release Earnings on Wednesday

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) is expected to announce its Q1 2026 earnings results before the market opens on Wednesday, July 30th. Analysts expect the company to announce earnings of $0.47 per share and revenue of $7.96 billion for the quarter. Takeda Pharmaceutical has set its FY 2025 guidance at 3.180-3.180 EPS.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 10.64% and a net margin of 2.36%. The company had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. On average, analysts expect Takeda Pharmaceutical to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Takeda Pharmaceutical Stock Performance

NYSE TAK traded down $0.20 during trading hours on Friday, hitting $14.47. The company had a trading volume of 6,382,852 shares, compared to its average volume of 2,182,939. Takeda Pharmaceutical has a fifty-two week low of $12.80 and a fifty-two week high of $15.53. The company has a quick ratio of 0.52, a current ratio of 1.01 and a debt-to-equity ratio of 0.57. The business has a fifty day simple moving average of $14.89 and a 200-day simple moving average of $14.47. The firm has a market cap of $46.03 billion, a P/E ratio of 65.75 and a beta of 0.23.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its stake in Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company's stock valued at $79,120,000 after buying an additional 692,404 shares in the last quarter. Royal Bank of Canada lifted its stake in Takeda Pharmaceutical by 11.0% in the 1st quarter. Royal Bank of Canada now owns 441,054 shares of the company's stock worth $6,558,000 after acquiring an additional 43,706 shares in the last quarter. AQR Capital Management LLC lifted its stake in Takeda Pharmaceutical by 43.6% in the 1st quarter. AQR Capital Management LLC now owns 195,740 shares of the company's stock worth $2,911,000 after acquiring an additional 59,442 shares in the last quarter. Finally, Focus Partners Wealth lifted its stake in Takeda Pharmaceutical by 4.1% in the 1st quarter. Focus Partners Wealth now owns 82,738 shares of the company's stock worth $1,230,000 after acquiring an additional 3,239 shares in the last quarter. Institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.